Fig. 1From: Prostate-specific antigen nadir within 1 year of radiotherapy combined with hormone therapy predicts cancer-specific mortality and biochemical recurrence-free survival in prostate cancer patientsUnivariate analysis assessing the ability of nPSA levels (≤ 0.06 ng/mL or > 0.06 ng/mL) to predict OS, PCSM, and BRFS.Back to article page